SALK NEWS

Salk Institute for Biological Studies - SALK NEWS

Salk News


Novel technique helps explain why bright light keeps us awake

LA JOLLA—In recent decades, scientists have learned a great deal about how different neurons connect and send signals to each other. But it’s been difficult to trace the activity of individual nerve fibers known as axons, some of which can extend from the tip of the toe to the head. Understanding these connections is important for figuring out how the brain receives and responds to signals from other parts of the body.


Salk scientist Tony Hunter receives National Cancer Institute Outstanding Investigator Award

LA JOLLA, CA—Salk scientist Tony Hunter has received a National Cancer Institute (NCI) Outstanding Investigator Award (OIA), which supports accomplished leaders in cancer research. Hunter, who is an American Cancer Society Professor, will receive more than $7,500,000 over the next seven years to further his work. According to the NCI, the award supports investigators who are providing significant contributions toward understanding cancer and developing applications that may lead to a breakthrough in cancer research.


Mapping normal breast development to better understand cancer

LA JOLLA—Breast cancer is one of the most prevalent cancers, and some forms rank among the most difficult to treat. Its various types and involvement of many different cells makes targeting such tumors difficult. Now, Salk Institute researchers have used a state-of-the-art technology to profile each cell during normal breast development in order to understand what goes wrong in cancer.


Machine learning helps plant science turn over a new leaf

LA JOLLA—Father of genetics Gregor Mendel spent years tediously observing and measuring pea plant traits by hand in the 1800s to uncover the basics of genetic inheritance. Today, botanists can track the traits, or phenotypes, of hundreds or thousands of plants much more quickly, with automated camera systems. Now, Salk researchers have helped speed up plant phenotyping even more, with machine-learning algorithms that teach a computer system to analyze three-dimensional shapes of the branches and leaves of a plant. The study, published in Plant Physiology on October 7, 2019, may help scientists better quantify how plants respond to climate change, genetic mutations or other factors.


Salk scientists find way to quantify how well cutting-edge microscopy technique works

LA JOLLA—In 2017, Salk scientists reported that tilting a frozen protein sample as it sat under an electron microscope was an effective approach to acquiring better information about its structure and helping researchers understand a host of diseases ranging from HIV to cancer. Now, they have developed a mathematical framework that underlies some of those initial observations.


Discovery of how colorectal cancer drug works will help more patients

LA JOLLA—Colorectal cancer is a common lethal disease, and treatment decisions are increasingly influenced by which genes are mutated within each patient. Some patients with a certain gene mutation benefit from a chemotherapy drug called cetuximab, although the mechanism of how this drug worked was unknown.


How emotion affects action

LA JOLLA—During high stress situations such as making a goal in soccer, some athletes experience a rapid decline in performance under pressure, known as “choking.” Now, Salk Institute researchers have uncovered what might be behind the phenomenon: one-way signals from the brain’s emotion circuit to the movement circuit. The study, which was published online on September 6, 2019, in eLife, could lead to new strategies for treating disorders with disrupted movement, such as obsessive-compulsive disorder, anxiety and depression, along with aiding in recovery from spinal cord injuries or physical performance under pressure.


Salk mourns the loss of postgrad alumnus

Daniel Lackner, a former Salk postdoctoral fellow who worked in the lab of Jan Karlseder from 2008 to 2014, passed away August 31 from complications related to a rare teratoid tumor.


Salk scientists develop technique to reveal epigenetic features of cells in the brain

LA JOLLA—The brain’s prefrontal cortex, which gives us our ability to solve problems and plan ahead, contains billions of cells. But understanding the large diversity of cell types in this critical region, each with unique genetic and molecular properties, has been challenging.


Key enzyme found in plants could guide development of medicines and other products

LA JOLLA—Plants can do many amazing things. Among their talents, they can manufacture compounds that help them repel pests, attract pollinators, cure infections and protect themselves from excess temperatures, drought and other hazards in the environment.


Getting to the root of how plants tolerate too much iron

LA JOLLA—Iron is essential for plant growth, but with heavy rainfall and poor aeration, many acidic soils become toxic with excess iron. In countries with dramatic flood seasons, such as in West Africa and tropical Asia, toxic iron levels can have dire consequences on the availability of staple foods, such as rice.


The Kavli Foundation gifts Salk $3 million for cutting-edge neuroscience research

LA JOLLA—The Salk Institute announced today that The Kavli Foundation has committed $3 million to support ongoing neuroscience research at Salk as part of the joint UCSD-Salk Kavli Institute for Brain and Mind (KIBM). The gift—matched by an additional $3 million from Salk—will add $6 million to the KIBM Endowment, to enable faculty in neuroscience to work on the most impactful questions in the field. The Kavli Institute for Brain and Mind was established through a $15.5 million endowment commitment from The Kavli Foundation, shared between Salk and UC San Diego.


New target for autoimmune disease could enable therapies with fewer side effects

LA JOLLA—Your immune system comes ready for battle against bacteria, viruses, fungi and even cancer. But in cases of autoimmune disease, the immune system’s superpowers turn it into a supervillain. Now, Salk Institute scientists have discovered a way to stop certain immune system cells from mistakenly attacking the body. Their findings, published the week of August 26, 2019, in the journal Proceedings of the National Academy of Sciences, suggest a new way to target Th17 helper T cells, a type of immune cell that produces interleukin 17, a molecule known to be at the root of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. Previous efforts targeting Th17 helper T cells have had limited success.


A novel technology for genome-editing a broad range of mutations in live organisms

LA JOLLA—The ability to edit genes in living organisms offers the opportunity to treat a plethora of inherited diseases. However, many types of gene-editing tools are unable to target critical areas of DNA, and creating such a technology has been difficult as living tissue contains diverse types of cells.


Brain’s astrocytes play starring role in long-term memory

LA JOLLA—Star-shaped cells called astrocytes help the brain establish long-lasting memories, Salk researchers have discovered. The new work adds to a growing body of evidence that astrocytes, long considered to be merely supportive cells in the brain, may have more of a leading role. The study, published in the journal GLIA on July 26, 2019, could inform therapies for disorders in which long-term memory is impaired, such as traumatic brain injury or dementia.


Scratching the surface of how your brain senses an itch

LA JOLLA—Light touch plays a critical role in everyday tasks, such as picking up a glass or playing a musical instrument. The sensation is also an essential part of the body’s protective defense system, alerting us to objects in our environment that could cause us to fall or injure ourselves. In addition, it is part of the detection system that has evolved to protect us from biting insects, such as those that cause malaria and Lyme disease, by eliciting a feeling of an itch when an insect lands on your skin.


Salk scientists Margarita Behrens and Joseph Ecker to receive over $1.6 million from Chan Zuckerberg Initiative to expand Human Cell Atlas

LA JOLLA–Joseph Ecker, professor and director of Salk’s Genomic Analysis Laboratory and Margarita Behrens, a research professor in Salk’s Computational Neurobiology Laboratory, will receive over $1.6 million over three years as part of a Seed Network Grant from the Chan Zuckerberg Initiative (CZI).


Finding a cause of neurodevelopmental disorders

LA JOLLA—Neurodevelopmental disorders arising from rare genetic mutations can cause atypical cognitive function, intellectual disability, and developmental delays, yet it is unclear why and how this happens. Scientists suspected a mutation in a complex of proteins could be the culprit for a group of rare genetic disorders and, now, Salk Institute researchers have identified the molecular mechanism linking this mutation with abnormal nervous system development. The team’s findings, published in Molecular Cell on July 30, 2019, bring researchers one step closer to understanding neurodevelopmental disorders, such as Nicolaides-Baraitser syndrome and others.


Two therapeutic targets identified for deadly lung cancer

LA JOLLA—The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Salk Institute researchers have now discovered precisely why inactive LKB1 results in cancer development. The surprising results, published in the online version of Cancer Discovery on July 26, 2019, highlight how LBK1 communicates with two enzymes that suppress inflammation in addition to cell growth, to block tumor growth. The findings could lead to new therapies for NSCLC, and you can see news coverage of the story here.


Unlocking therapies for hard-to-treat lung cancers

LA JOLLAAround 85 percent of lung cancers are classified as non-small-cell lung cancers, or NSCLCs. Some patients with these cancers can be treated with targeted genetic therapies, and some benefit from immunotherapies—but the vast majority of NSCLC patients have no treatment options except for chemotherapy.